Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Tafluprost (S01ee05) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredients Timolol and Brinzolamide (S01ed67) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Vilanterol and Umeclidinium Bromide, Atc R03al03

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Melatonin (N05ch01), Excluding Prolonged-Release Tablets with an Effective Strength of 2Mg...

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Ciclosporin (S01xa18) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Dronedarone, Atc C01bd07

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicinal Products with the Active Ingredients Lamivudine, Tenofovir Disoproxil and Doravirine (J05ar24) as Part of a So-Called...

Open House Discount Contracts 2024-06

Open House Drug Discount Agreements Oxycodone and Naloxone, Atc N02aa55

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fondaparinux, Atc B01ax05 for the Period June 1St, 2024 - May 31St, 2026